Latest Heart News
TUESDAY, May 4, 2021
At issue are prescription-strength omega-3 fatty acids, which are naturally found in fish oil. The medications are often prescribed to people with very high triglycerides, a type of blood fat linked to increased risk of heart attack and stroke.
According to the American Heart Association, prescription omega-3s can lower triglycerides by 20% to 30% in most people.
But the medications are also controversial, because their ultimate benefits for the heart are unclear.
Now the new study — an analysis of five past clinical trials — suggests caution is in order. Overall, trial patients given omega-3s were over one-third more likely to develop atrial fibrillation (a-fib) than those given a placebo. The fish oil doses taken ranged from 0.84 grams to 4 grams per day.
A-fib is not immediately life-threatening, but it's "not benign," either, said Dave Dixon, one of the researchers on the study and an associate professor at Virginia Commonwealth University (VCU), in Richmond.
However, the increased risk was fairly consistent across the trials — more consistent, in fact, than heart benefits were, said co-researcher Salvatore Carbone, an assistant professor at VCU.
But when the researchers pooled the results of all five trials, there was a clear result: Omega-3 patients were 37% more likely to develop a-fib than placebo patients were.
In contrast, only one trial showed that an omega-3 product could cut the risks of other heart conditions.
In that trial, dubbed REDUCE-IT, patients using a product called Vascepa (icosapent ethyl) saw their risk of "cardiovascular events" drop by 25%. That included heart attack, stroke and death from cardiovascular causes.
Even in that study, though, a-fib risk rose among omega-3 users, by 35%.
Why has only one trial found heart benefits? Again, it's not yet clear, Dixon said.
But, he added, Vascepa is different from the fish oil products tested in the other trials. It contains only one omega-3, called EPA, while the other products contain a combination of EPA and DHA.
And in the REDUCE-IT trial, Dixon said, higher levels of EPA in patients' blood correlated to lower cardiovascular risks.
That hints, he said, that focusing on EPA might be "the way to go in the future." But the conflicting findings on the benefits of omega-3s — along with the potential risk of a-fib — highlight the need for more studies, the researchers said.
The analysis was published April 29 in the European Heart Journal — Cardiovascular Pharmacotherapy.
Findings on the heart benefits of fish oil have indeed been "inconsistent," said Linda Van Horn, a member of the heart association's nutrition committee and a professor at Northwestern University Feinberg School of Medicine, in Chicago.
"There are limited and inconsistent data regarding the benefit or risk of taking fish oil supplements," Van Horn said.
So the heart association recommends eating two servings of fish a week instead. Van Horn said that fatty fish, such as salmon, trout, albacore tuna and herring, are the best sources of omega-3s.
"We don't know if over-the-counter products could have these same effects," he said.
Over-the-counter fish oil is considered a dietary supplement, so it is not regulated by the U.S. Food and Drug Administration as a drug would be, Dixon pointed out.
Both he and Carbone said it's best to talk to a doctor or pharmacist before starting any fish oil product — and that people on prescription omega-3s should speak with their doctor before stopping.
Harvard Medical School has more on fish oil and heart health.
SOURCES: Salvatore Carbone, PhD, assistant professor, kinesiology and health sciences, Virginia Commonwealth University, Richmond, Va.; Dave L. Dixon, PharmD, associate professor, ambulatory care, and vice-chair, clinical services, department of pharmacotherapy and outcomes science, Virginia Commonwealth University, Richmond, Va.; Linda Van Horn, PhD, RD, professor and chief, nutrition division, department of preventive medicine, Northwestern University Feinberg School of Medicine, Chicago, and member, Nutrition Committee, American Heart Association, Dallas; European Heart Journal—Cardiovascular Pharmacotherapy, April 29, 2021, online
Copyright © 2021 HealthDay. All rights reserved.